Source: GlobalData
Parkinson’s disease market across 7MM to grow at 8.9% CAGR during 2023-33, forecasts GlobalData
Posted in Pharma
The Parkinson’s disease (PD) market across the seven major markets (7MM*) is projected to grow at a compound annual growth rate (CAGR) of 8.9% from $3.4 billion in 2023 to $7.9 billion in 2033, driven by the introduction of 10 pipeline products, the increased adoption of novel levodopa delivery methods, and the rising prevalence of PD due to the aging population across the 7MM, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, “Parkinson’s Disease: Seven-Market Drug Forecast and Market Analysis,” anticipates an increase in sales across most currently marketed PD drug classes. Specifically, levodopa therapies, catechol-o-methyltransferase (COMT) inhibitors, dopamine agonists, monoamine oxidase B (MOA-B) inhibitors, other antiparkinsonian agents, and PD dementia agents.
Among the pre-existing drug-classes, the agents targeting PD dementia are expected to see the greatest growth with a CAGR of 24.5% during the forecast period. Additionally, the launch of 10 late-stage pipeline therapies—including two disease-modifying therapies (DMT) and several symptomatic treatments targeting diverse PD needs—will collectively drive an estimated $3.5 billion in sales by 2033.
Lorraine Palmer, Pharma Analyst at GlobalData, comments: “The treatment of PD dementia is consistently rated one of the highest unmet needs by key opinion leaders (KOLs) and high-prescribers. Currently, there is only one agent, rivastigmine, indicated for the treatment of PD dementia within the 7MM. However, it is anticipated that two agents—Anavex’s blarcamesine and Irlab Therapeutics’s pirepemat—targeting PD dementia will launch by 2033.”
The expansion of the levodopa delivery system AbbVie’s Produodopa/Vyalev across the 7MM (following its launch in Japan in 2023, expansion into the 5EU in 2024, and anticipated launch in the US in 2025) is expected to drive it into the highest-grossing PD treatment by 2033, with projected sales of $1.2 billion by 2033. This also reflects strong enthusiasm from KOLs regarding its broader availability.
Palmer adds: “The anticipated launch of Roche/Prothena’s prasinezumab and Annovis Bio’s buntanetap as the first DMTs for PD will reshape the treatment space. These treatments aim to address the underlying biology of the disease by targeting α-synuclein aggregation, a key factor in disease progression. While KOL opinions are divided on their efficacy, the introduction of these DMTs will be an important step towards addressing the field’s most pressing unmet need. Therefore, it is expected that these two therapies alone will make up a large portion of the market come 2033. GlobalData forecasts sales of $1.5 billion by 2033.”
GlobalData’s analysis also highlights the growing prevalence of PD, with diagnosed cases expected to increase from 2.6 million in 2023 to 3.1 million by 2033 across the 7MM. The number of treated cases is forecasted to rise in parallel, from 1.9 million in 2023 to 2.3 million in 2033, reflecting the aging population within the 7MM.
However, the patent expiry of key therapies including Nuplazid (pimavanserin), Rytary (carbidopa/levodopa), Ongentys (opicapone), and Xadago (safinamide mesylate) is expected to curtail the market growth. Collectively, the therapies anticipated to lose their patent protection within the forecast period accounted for $1.1 billion in 2023 sales across the 7MM but are forecasted to decline to $202.8 million by 2033.
Palmer concludes: “The PD market is extremely dynamic. However, the next decade is promising transformative growth. With the expansion and launch of groundbreaking therapies, particularly DMTs and novel mechanisms of action to address PD dementia and motor complications. The late-stage pipeline is well positioned to meet the needs of a growing patient population.”
*7MM = The US, France, Germany, Italy, Spain, the UK, and Japan.